To Abreviate or not to Abreviate [Regulatives / Guidelines]

posted by GSTATS Homepage – India, 2010-05-27 20:30 (5873 d 08:56 ago) – Posting: # 5389
Views: 18,653

Dear KR,

As per my understanding, if i am not wrong FDA wants you to conduct a three way crossover study with two doses of reference and then fitting an Emax model (as given in recommendation) for reference which will provide estimated values of parameters used in model.
Put those estimated values again in model for test product as response and find relative bioavailability (F) of test with respect to reference.

And 90% confidence intervals for "F" can be calculated by repetitive sampling method using Bootstrap procedure.

I hope this will help you.

Regards,
GSTATS
http://gstatsolutions.com/Medical%20Research.html

Let Noble Thoughts come from Every Side: RIG VEDA

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
123 visitors (0 registered, 123 guests [including 14 identified bots]).
Forum time: 05:26 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5